Genomics Bioscience & Technology Co

Genomics Bioscience & Technology Co Rule of 40

The Rule of 40 of Genomics Bioscience & Technology Co (4195.TWO) as of Oct 21, 2026 is 26.33 %. In the previous year, Rule of 40 was 3.56 % — a change of 638.70% (higher).

Rule of 40

26.33 %

YoY

638.70%

Last updated:

Rule of 40 of Genomics Bioscience & Technology Co is 2025 26.33 % . Rule of 40 of Genomics Bioscience & Technology Co was 2024 3.56 % . It decreases by 638.70% higher compared to the previous year.

The Genomics Bioscience & Technology Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-25.50 TWD
Jan 1, 2019
15.91 TWD
Jan 1, 2020
4.07 TWD
Jan 1, 2021
-8.62 TWD
Jan 1, 2022
25.61 TWD
Jan 1, 2023
-47.42 TWD
Jan 1, 2024
3.56 TWD
Jan 1, 2025
26.33 TWD
The Genomics Bioscience & Technology Co Rule of 40 history
YEARRule of 40YoY
26.33 %+638.70%
3.56 %-107.52%
-47.42 %-285.18%
25.61 %-396.92%
-8.62 %-311.88%
4.07 %-74.41%
15.91 %-162.37%
-25.50 %-432.21%
7.68 %-140.35%
-19.02 %-208.13%
17.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomics Bioscience & Technology Co Stock analysis

What does Genomics Bioscience & Technology Co do? Genomics BioSci & Tech.Co., Ltd. generates revenue through the provision of public gene sequencing and clinical sequencing services, including preventive genetic testing, primer synthesis, and individualized medical and genetic screening for cancers. The company also manufactures and sells biochemical instruments, reagents, and consumables, distributing these products domestically and internationally. Its primary customers are healthcare providers and research institutions seeking genetic analysis and diagnostic solutions. The firm's services and products target both public health initiatives and specialized medical applications in oncology and preventive care. The company's revenue streams are derived from its core biotechnological services and product sales, with a focus on domestic and overseas markets. Public gene sequencing services cater to broader health screening needs, while clinical sequencing services address specific medical conditions, particularly cancer-related genetic screening. The firm's biochemical instruments and reagents support laboratory operations in both research and clinical settings, serving a diverse clientele across multiple healthcare segments. Genomics Bioscience & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomics Bioscience & Technology Co stock

Rule of 40 of Genomics Bioscience & Technology Co is 26.33 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Genomics Bioscience & Technology Co

All Key Metrics — Genomics Bioscience & Technology Co